{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T09:25:11Z","timestamp":1768901111317,"version":"3.49.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,8,24]]},"DOI":"10.7759\/cureus.28358","type":"journal-article","created":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T21:14:07Z","timestamp":1661375647000},"source":"Crossref","is-referenced-by-count":10,"title":["Kawasaki Disease and Coronary Artery Involvement: A Narrative Review"],"prefix":"10.7759","author":[{"given":"Kruthiga","family":"Rajasekaran","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shrimahitha","family":"Duraiyarasan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mayowa","family":"Adefuye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nisha","family":"Manjunatha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vinutna","family":"Ganduri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2017.1232165","article-title":"Kawasaki disease: etiopathogenesis and novel treatment strategies","volume":"13","author":"Agarwal S","year":"2017","unstructured":"Agarwal S, Agrawal DK. Kawasaki disease: etiopathogenesis and novel treatment strategies. Expert Rev Clin Immunol. 2017, 13:247-58. 10.1080\/1744666X.2017.1232165","journal-title":"Expert Rev Clin Immunol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.13214","article-title":"History of the worldwide emergence of Kawasaki disease","volume":"21","author":"Burns JC","year":"2018","unstructured":"Burns JC. History of the worldwide emergence of Kawasaki disease. Int J Rheum Dis. 2018, 21:13-5. 10.1111\/1756-185X.13214","journal-title":"Int J Rheum Dis"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2011.04361.x","article-title":"Pathogenesis of Kawasaki disease","volume":"164 Suppl 1","author":"Takahashi K","year":"2011","unstructured":"Takahashi K, Oharaseki T, Yokouchi Y. Pathogenesis of Kawasaki disease. Clin Exp Immunol. 2011, 164 Suppl 1:20-2. 10.1111\/j.1365-2249.2011.04361.x","journal-title":"Clin Exp Immunol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/ped.13544","article-title":"Epidemiological observations of Kawasaki disease in Japan, 2013-2014","volume":"60","author":"Makino N","year":"2018","unstructured":"Makino N, Nakamura Y, Yashiro M, et al.. Epidemiological observations of Kawasaki disease in Japan, 2013-2014. Pediatr Int. 2018, 60:581-7. 10.1111\/ped.13544","journal-title":"Pediatr Int"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e3181cf8705","article-title":"Hospitalizations for Kawasaki syndrome among children in the United States, 1997-2007","volume":"29","author":"Holman RC","year":"2010","unstructured":"Holman RC, Belay ED, Christensen KY, Folkema AM, Steiner CA, Schonberger LB. Hospitalizations for Kawasaki syndrome among children in the United States, 1997-2007. Pediatr Infect Dis J. 2010, 29:483-8. 10.1097\/INF.0b013e3181cf8705","journal-title":"Pediatr Infect Dis J"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222212334","article-title":"Hygiene hypothesis as the etiology of Kawasaki disease: dysregulation of early b cell development","volume":"22","author":"Lee JK","year":"2021","unstructured":"Lee JK. Hygiene hypothesis as the etiology of Kawasaki disease: dysregulation of early b cell development. Int J Mol Sci. 2021, 22:10.3390\/ijms222212334","journal-title":"Int J Mol Sci"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/iid3.373","article-title":"Five immune-gene-signatures participate\u00a0in the development and pathogenesis of Kawasaki disease","volume":"9","author":"Nie H","year":"2021","unstructured":"Nie H, Wang S, Wu Q, Xue D, Zhou W. Five immune-gene-signatures participate\u00a0in the development and pathogenesis of Kawasaki disease. Immun Inflamm Dis. 2021, 9:157-66. 10.1002\/iid3.373","journal-title":"Immun Inflamm Dis"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.pedneo.2011.11.003","article-title":"Kawasaki disease: an update on diagnosis and treatment","volume":"53","author":"Kuo HC","year":"2012","unstructured":"Kuo HC, Yang KD, Chang WC, Ger LP, Hsieh KS. Kawasaki disease: an update on diagnosis and treatment. Pediatr Neonatol. 2012, 53:4-11. 10.1016\/j.pedneo.2011.11.003","journal-title":"Pediatr Neonatol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000145143.19711.78","article-title":"Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association","volume":"110","author":"Newburger JW","year":"2004","unstructured":"Newburger JW, Takahashi M, Gerber MA, et al.. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation. 2004, 110:2747-71. 10.1161\/01.CIR.0000145143.19711.78","journal-title":"Circulation"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1038\/srep43732","article-title":"Identification of candidate diagnostic serum biomarkers for Kawasaki disease using proteomic analysis","volume":"7","author":"Kimura Y","year":"2017","unstructured":"Kimura Y, Yanagimachi M, Ino Y, et al.. Identification of candidate diagnostic serum biomarkers for Kawasaki disease using proteomic analysis. Sci Rep. 2017, 7:43732. 10.1038\/srep43732","journal-title":"Sci Rep"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1136\/archdischild-2012-302841","article-title":"Management of Kawasaki disease","volume":"99","author":"Eleftheriou D","year":"2014","unstructured":"Eleftheriou D, Levin M, Shingadia D, Tulloh R, Klein NJ, Brogan PA. Management of Kawasaki disease. Arch Dis Child. 2014, 99:74-83. 10.1136\/archdischild-2012-302841","journal-title":"Arch Dis Child"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1186\/s12887-020-02285-5","article-title":"Neutrophil-to-lymphocyte ratio and scoring system for\u00a0predicting coronary artery lesions of Kawasaki\u00a0disease","volume":"20","author":"Chang LS","year":"2020","unstructured":"Chang LS, Lin YJ, Yan JH, Guo MM, Lo MH, Kuo HC. Neutrophil-to-lymphocyte ratio and scoring system for\u00a0predicting coronary artery lesions of Kawasaki\u00a0disease. BMC Pediatr. 2020, 20:398. 10.1186\/s12887-020-02285-5","journal-title":"BMC Pediatr"},{"key":"ref13","article-title":"Report of the Subcommittee on Standardization of Diagnostic Criteria and Reporting of Coronary Artery Lesions in Kawasaki Disease","author":"Research Committee on Kawasaki Disease","year":"1984","unstructured":"Research Committee on Kawasaki Disease. Report of the Subcommittee on Standardization of Diagnostic Criteria and Reporting of Coronary Artery Lesions in Kawasaki Disease. Ministry of Health and Welfare, Tokyo; 1984."},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00126","article-title":"Molecular interactions between complement factor h and its heparin and heparan sulfate ligands","volume":"5","author":"Perkins SJ","year":"2014","unstructured":"Perkins SJ, Fung KW, Khan S. Molecular interactions between complement factor h and its heparin and heparan sulfate ligands. Front Immunol. 2014, 5:126. 10.3389\/fimmu.2014.00126","journal-title":"Front Immunol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1002\/art.21529","article-title":"Polymorphisms in the mannose-binding lectin gene as determinants of age-defined risk of coronary artery lesions in Kawasaki disease","volume":"54","author":"Biezeveld MH","year":"2006","unstructured":"Biezeveld MH, Geissler J, Weverling GJ, Kuipers IM, Lam J, Ottenkamp J, Kuijpers TW. Polymorphisms in the mannose-binding lectin gene as determinants of age-defined risk of coronary artery lesions in Kawasaki disease. Arthritis Rheum. 2006, 54:369-76. 10.1002\/art.21529","journal-title":"Arthritis Rheum"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0167187","article-title":"The central role of kng1 gene as a genetic determinant of coagulation pathway-related traits: exploring meta phenotypes","volume":"11","author":"Brunel H","year":"2016","unstructured":"Brunel H, Massanet R, Martinez-Perez A, et al.. The central role of kng1 gene as a genetic determinant of coagulation pathway-related traits: exploring meta phenotypes. PLoS One. 2016, 11:e0167187. 10.1371\/journal.pone.0167187","journal-title":"PLoS One"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1111\/j.1751-553X.2011.01307.x","article-title":"The phenotypic and genetic assessment of antithrombin deficiency","volume":"33","author":"Cooper PC","year":"2011","unstructured":"Cooper PC, Coath F, Daly ME, Makris M. The phenotypic and genetic assessment of antithrombin deficiency. Int J Lab Hematol. 2011, 33:227-37. 10.1111\/j.1751-553X.2011.01307.x","journal-title":"Int J Lab Hematol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-016-3368-7","article-title":"Identification of mutations in FN1 leading to glomerulopathy with fibronectin deposits","volume":"31","author":"Ohtsubo H","year":"2016","unstructured":"Ohtsubo H, Okada T, Nozu K, et al.. Identification of mutations in FN1 leading to glomerulopathy with fibronectin deposits. Pediatr Nephrol. 2016, 31:1459-67. 10.1007\/s00467-016-3368-7","journal-title":"Pediatr Nephrol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1038\/aps.2011.93","article-title":"Genetic polymorphisms in Kawasaki disease","volume":"32","author":"Kuo HC","year":"2011","unstructured":"Kuo HC, Chang WC. Genetic polymorphisms in Kawasaki disease. Acta Pharmacol Sin. 2011, 32:1193-8. 10.1038\/aps.2011.93","journal-title":"Acta Pharmacol Sin"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCGENETICS.110.940858","article-title":"Transforming growth factor-beta signaling pathway in patients with Kawasaki disease","volume":"4","author":"Shimizu C","year":"2011","unstructured":"Shimizu C, Jain S, Davila S, et al.. Transforming growth factor-beta signaling pathway in patients with Kawasaki disease. Circ Cardiovasc Genet. 2011, 4:16-25. 10.1161\/CIRCGENETICS.110.940858","journal-title":"Circ Cardiovasc Genet"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1038\/nri1632","article-title":"NFAT proteins: key regulators of T-cell development and function","volume":"5","author":"Macian F","year":"2005","unstructured":"Macian F. NFAT proteins: key regulators of T-cell development and function. Nat Rev Immunol. 2005, 5:472-84. 10.1038\/nri1632","journal-title":"Nat Rev Immunol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-016-3430-6","article-title":"Pro-brain natriuretic peptide (ProBNP) levels in North Indian children with Kawasaki disease","volume":"36","author":"Reddy M","year":"2016","unstructured":"Reddy M, Singh S, Rawat A, Sharma A, Suri D, Rohit MK. Pro-brain natriuretic peptide (ProBNP) levels in North Indian children with Kawasaki disease. Rheumatol Int. 2016, 36:551-9. 10.1007\/s00296-016-3430-6","journal-title":"Rheumatol Int"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000000233","article-title":"Periostin is upregulated in coronary arteriopathy in Kawasaki disease and is a potential diagnostic biomarker","volume":"33","author":"Reindel R","year":"2014","unstructured":"Reindel R, Kim KY, Baker SC, et al.. Periostin is upregulated in coronary arteriopathy in Kawasaki disease and is a potential diagnostic biomarker. Pediatr Infect Dis J. 2014, 33:659-61. 10.1097\/INF.0000000000000233","journal-title":"Pediatr Infect Dis J"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1007\/s00246-010-9769-7","article-title":"Plasma clusterin levels in predicting the occurrence of coronary artery lesions in patients with Kawasaki disease","volume":"31","author":"Yu HR","year":"2010","unstructured":"Yu HR, Kuo HC, Huang EY, et al.. Plasma clusterin levels in predicting the occurrence of coronary artery lesions in patients with Kawasaki disease. Pediatr Cardiol. 2010, 31:1151-6. 10.1007\/s00246-010-9769-7","journal-title":"Pediatr Cardiol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.carpath.2018.10.005","article-title":"Expression of tenascin C in cardiovascular lesions of Kawasaki disease","volume":"38","author":"Yokouchi Y","year":"2019","unstructured":"Yokouchi Y, Oharaseki T, Enomoto Y, Sato W, Imanaka-Yoshida K, Takahashi K. Expression of tenascin C in cardiovascular lesions of Kawasaki disease. Cardiovasc Pathol. 2019, 38:25-30. 10.1016\/j.carpath.2018.10.005","journal-title":"Cardiovasc Pathol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2010.04236.x","article-title":"The T helper type 17\/regulatory T cell imbalance in patients with acute Kawasaki disease","volume":"162","author":"Jia S","year":"2010","unstructured":"Jia S, Li C, Wang G, Yang J, Zu Y. The T helper type 17\/regulatory T cell imbalance in patients with acute Kawasaki disease. Clin Exp Immunol. 2010, 162:131-7. 10.1111\/j.1365-2249.2010.04236.x","journal-title":"Clin Exp Immunol"},{"key":"ref27","article-title":"Defective FOXP3 expression in patients with acute Kawasaki disease and restoration by intravenous immunoglobulin therapy","volume":"28","author":"Olivito B","year":"2010","unstructured":"Olivito B, Taddio A, Simonini G, et al.. Defective FOXP3 expression in patients with acute Kawasaki disease and restoration by intravenous immunoglobulin therapy. Clin Exp Rheumatol. 2010, 28:93-7.","journal-title":"Clin Exp Rheumatol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2008.11.010","article-title":"Foxp3-dependent microRNA155 confers competitive fitness to regulatory T cells by targeting SOCS1 protein","volume":"30","author":"Lu LF","year":"2009","unstructured":"Lu LF, Thai TH, Calado DP, et al.. Foxp3-dependent microRNA155 confers competitive fitness to regulatory T cells by targeting SOCS1 protein. Immunity. 2009, 30:80-91. 10.1016\/j.immuni.2008.11.010","journal-title":"Immunity"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0803162","article-title":"Cutting edge: the Foxp3 target miR-155 contributes to the development of regulatory T cells","volume":"182","author":"Kohlhaas S","year":"2009","unstructured":"Kohlhaas S, Garden OA, Scudamore C, Turner M, Okkenhaug K, Vigorito E. Cutting edge: the Foxp3 target miR-155 contributes to the development of regulatory T cells. J Immunol. 2009, 182:2578-82. 10.4049\/jimmunol.0803162","journal-title":"J Immunol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.120.316951","article-title":"Reduced Platelet mir-223 induction in kawasaki disease leads to severe coronary artery pathology through a mir-223\/pdgefr\u03b2 vascular smooth muscle cell axis","volume":"127","author":"Zhang Y","year":"2020","unstructured":"Zhang Y, Wang Y, Zhang L, et al.. Reduced Platelet mir-223 induction in kawasaki disease leads to severe coronary artery pathology through a mir-223\/pdgefr\u03b2 vascular smooth muscle cell axis. Circ Res. 2020, 127:855-73. 10.1161\/CIRCRESAHA.120.316951","journal-title":"Circ Res"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.12997\/jla.2019.8.1.50","article-title":"Analysis of circular RNAs in the coronary arteries of patients with Kawasaki disease","volume":"8","author":"Kim YK","year":"2019","unstructured":"Kim YK. Analysis of circular RNAs in the coronary arteries of patients with Kawasaki disease. J Lipid Atheroscler. 2019, 8:50-7. 10.12997\/jla.2019.8.1.50","journal-title":"J Lipid Atheroscler"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-0039.1992.tb01915.x","article-title":"The HLA class II region and susceptibility to Kawasaki disease","volume":"39","author":"Fildes N","year":"1992","unstructured":"Fildes N, Burns JC, Newburger JW, Klitz W, Begovich AB. The HLA class II region and susceptibility to Kawasaki disease. Tissue Antigens. 1992, 39:99-101. 10.1111\/j.1399-0039.1992.tb01915.x","journal-title":"Tissue Antigens"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1253\/jcj.43.633","article-title":"Pathology of Kawasaki disease: I. pathology and morphogenesis of the vascular changes","volume":"43","author":"Amano S","year":"1979","unstructured":"Amano S, Hazama F, Hamashima Y. Pathology of Kawasaki disease: I. pathology and morphogenesis of the vascular changes. Jpn Circ J. 1979, 43:633-43. 10.1253\/jcj.43.633","journal-title":"Jpn Circ J"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.3389%2Ffped.2019.00242","article-title":"Relationship between ESR, CRP, platelet count and coronary artery disease in Kawasaki disease","volume":"15","author":"Rahbari-Manesh AA","year":"2019","unstructured":"Rahbari-Manesh AA, Salamati P, Ghaforian S, Zekavat M. Relationship between ESR, CRP, platelet count and coronary artery disease in Kawasaki disease. Iran J Pediatr. 2019, 15:139-44. 10.3389%2Ffped.2019.00242","journal-title":"Iran J Pediatr"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1111\/j.1442-200x.2005.02033.x","article-title":"Revision of diagnostic guidelines for Kawasaki disease (the 5th revised edition)","volume":"47","author":"Ayusawa M","year":"2005","unstructured":"Ayusawa M, Sonobe T, Uemura S, et al.. Revision of diagnostic guidelines for Kawasaki disease (the 5th revised edition). Pediatr Int. 2005, 47:232-4. 10.1111\/j.1442-200x.2005.02033.x","journal-title":"Pediatr Int"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1186\/s12947-016-0046-7","article-title":"Quantitative evaluation of myocardial fibrosis by cardiac integrated backscatter analysis in Kawasaki disease","volume":"14","author":"Xie L","year":"2016","unstructured":"Xie L, Wang R, Huang M, Zhang Y, Shen J, Xiao T. Quantitative evaluation of myocardial fibrosis by cardiac integrated backscatter analysis in Kawasaki disease. Cardiovasc Ultrasound. 2016, 14:3. 10.1186\/s12947-016-0046-7","journal-title":"Cardiovasc Ultrasound"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1253\/circj.cj-10-74-0903","article-title":"Guidelines for diagnosis and management of cardiovascular sequelae in Kawasaki disease (JCS 2008)--digest version","volume":"74","author":"JCS Joint Working Group","year":"2010","unstructured":"JCS Joint Working Group. Guidelines for diagnosis and management of cardiovascular sequelae in Kawasaki disease (JCS 2008)--digest version. Circ J. 2010, 74:1989-2020. 10.1253\/circj.cj-10-74-0903","journal-title":"Circ J"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000484","article-title":"Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association","volume":"135","author":"McCrindle BW","year":"2017","unstructured":"McCrindle BW, Rowley AH, Newburger JW, et al.. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association. Circulation. 2017, 135:e927-99. 10.1161\/CIR.0000000000000484","journal-title":"Circulation"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1111\/j.1442-200x.1991.tb02612.x","article-title":"Intravenous gamma-globulin treatment in Kawasaki disease","volume":"33","author":"Harada K","year":"1991","unstructured":"Harada K. Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatr Jpn. 1991, 33:805-10. 10.1111\/j.1442-200x.1991.tb02612.x","journal-title":"Acta Paediatr Jpn"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(84)91504-6","article-title":"High-dose intravenous gammaglobulin for kawasaki disease","volume":"2","author":"Furusho K","year":"1984","unstructured":"Furusho K, Kamiya T, Nakano H, et al.. High-dose intravenous gammaglobulin for kawasaki disease. Lancet. 1984, 2:1055-8. 10.1016\/s0140-6736(84)91504-6","journal-title":"Lancet"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1067\/mpd.2002.127505","article-title":"Decreased nitric oxide production after intravenous immunoglobulin treatment in patients with Kawasaki disease","volume":"141","author":"Wang CL","year":"2002","unstructured":"Wang CL, Wu YT, Lee CJ, Liu HC, Huang LT, Yang KD. Decreased nitric oxide production after intravenous immunoglobulin treatment in patients with Kawasaki disease. J Pediatr. 2002, 141:560-5. 10.1067\/mpd.2002.127505","journal-title":"J Pediatr"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1016\/s0022-3476(05)83532-2","article-title":"Economic evaluation of intravenous immune globulin therapy for Kawasaki syndrome","volume":"122","author":"Klassen TP","year":"1993","unstructured":"Klassen TP, Rowe PC, Gafni A. Economic evaluation of intravenous immune globulin therapy for Kawasaki syndrome. J Pediatr. 1993, 122:538-42. 10.1016\/s0022-3476(05)83532-2","journal-title":"J Pediatr"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1007\/s11908-016-0538-5","article-title":"The clinical diagnosis and management of Kawasaki disease: a review and update","volume":"18","author":"Zhu FH","year":"2016","unstructured":"Zhu FH, Ang JY. The clinical diagnosis and management of Kawasaki disease: a review and update. Curr Infect Dis Rep. 2016, 18:32. 10.1007\/s11908-016-0538-5","journal-title":"Curr Infect Dis Rep"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa003199","article-title":"Cyclooxygenase inhibitors and the antiplatelet effects of aspirin","volume":"345","author":"Catella-Lawson F","year":"2001","unstructured":"Catella-Lawson F, Reilly MP, Kapoor SC, et al.. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med. 2001, 345:1809-17. 10.1056\/NEJMoa003199","journal-title":"N Engl J Med"},{"key":"ref45","article-title":"Kawasaki disease with Reye syndrome: report of one case","volume":"33","author":"Lee JH","year":"1992","unstructured":"Lee JH, Hung HY, Huang FY. Kawasaki disease with Reye syndrome: report of one case. Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi. 1992, 33:67-71.","journal-title":"Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2012-302126","article-title":"Intravenous immunoglobulin plus corticosteroid to prevent coronary artery abnormalities in Kawasaki disease: a meta-analysis","volume":"99","author":"Chen S","year":"2013","unstructured":"Chen S, Dong Y, Yin Y, Krucoff MW. Intravenous immunoglobulin plus corticosteroid to prevent coronary artery abnormalities in Kawasaki disease: a meta-analysis. Heart. 2013, 99:76-82. 10.1136\/heartjnl-2012-302126","journal-title":"Heart"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1017\/S1047951117002864","article-title":"Usefulness and safety of anakinra in refractory Kawasaki disease complicated by coronary artery aneurysm","volume":"28","author":"Guillaume MP","year":"2018","unstructured":"Guillaume MP, Reumaux H, Dubos F. Usefulness and safety of anakinra in refractory Kawasaki disease complicated by coronary artery aneurysm. Cardiol Young. 2018, 28:739-42. 10.1017\/S1047951117002864","journal-title":"Cardiol Young"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2018.01.024","article-title":"The use of interleukin 1 receptor antagonist (anakinra) in Kawasaki disease: a retrospective cases series","volume":"17","author":"Kone-Paut I","year":"2018","unstructured":"Kone-Paut I, Cimaz R, Herberg J, et al.. The use of interleukin 1 receptor antagonist (anakinra) in Kawasaki disease: a retrospective cases series. Autoimmun Rev. 2018, 17:768-74. 10.1016\/j.autrev.2018.01.024","journal-title":"Autoimmun Rev"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2019-229708","article-title":"High-dose anakinra as treatment for macrophage activation syndrome caused by refractory Kawasaki disease in an infant","volume":"12","author":"Lind-Holst M","year":"2019","unstructured":"Lind-Holst M, Hartling UB, Christensen AE. High-dose anakinra as treatment for macrophage activation syndrome caused by refractory Kawasaki disease in an infant. BMJ Case Rep. 2019, 12:10.1136\/bcr-2019-229708","journal-title":"BMJ Case Rep"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1186\/s13256-019-2028-5","article-title":"Kawasaki disease triggered by parvovirus infection: an atypical case report of two siblings","volume":"13","author":"Maggio MC","year":"2019","unstructured":"Maggio MC, Cimaz R, Alaimo A, Comparato C, Di Lisi D, Corsello G. Kawasaki disease triggered by parvovirus infection: an atypical case report of two siblings. J Med Case Rep. 2019, 13:104. 10.1186\/s13256-019-2028-5","journal-title":"J Med Case Rep"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2020.00195","article-title":"Resolution of giant coronary aneurysms in a child with refractory Kawasaki disease treated with anakinra","volume":"8","author":"Gambacorta A","year":"2020","unstructured":"Gambacorta A, Buonsenso D, De Rosa G, et al.. Resolution of giant coronary aneurysms in a child with refractory Kawasaki disease treated with anakinra. Front Pediatr. 2020, 8:195. 10.3389\/fped.2020.00195","journal-title":"Front Pediatr"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(13)62298-9","article-title":"Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomized, double-blind, placebo-controlled trial","volume":"383","author":"Tremoulet AH","year":"2014","unstructured":"Tremoulet AH, Jain S, Jaggi P, et al.. Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomized, double-blind, placebo-controlled trial. Lancet. 2014, 383:1731-8. 10.1016\/s0140-6736(13)62298-9","journal-title":"Lancet"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2010.06.014","article-title":"Prospective open-label trial of etanercept as adjunctive therapy for Kawasaki disease","volume":"157","author":"Choueiter NF","year":"2010","unstructured":"Choueiter NF, Olson AK, Shen DD, Portman MA. Prospective open-label trial of etanercept as adjunctive therapy for Kawasaki disease. J Pediatr. 2010, 157:960-966.e1. 10.1016\/j.jpeds.2010.06.014","journal-title":"J Pediatr"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2012.02.048","article-title":"Calcineurin inhibitor treatment of intravenous immunoglobulin-resistant Kawasaki disease","volume":"161","author":"Tremoulet AH","year":"2012","unstructured":"Tremoulet AH, Pancoast P, Franco A, et al.. Calcineurin inhibitor treatment of intravenous immunoglobulin-resistant Kawasaki disease. J Pediatr. 2012, 161:506-512.e1. 10.1016\/j.jpeds.2012.02.048","journal-title":"J Pediatr"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/107127-kawasaki-disease-and-coronary-artery-involvement-a-narrative-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:48:58Z","timestamp":1707508138000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/107127-kawasaki-disease-and-coronary-artery-involvement-a-narrative-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,24]]},"references-count":54,"URL":"https:\/\/doi.org\/10.7759\/cureus.28358","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8,24]]}}}